Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03409614 · OUTCOME

Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer · Source last updated 2026-05-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
28 days

What was measured

Part 1 only

Analysis population: Only the first 10 participants enrolled in the Cemiplimab+AbbrevChemo+ipilimumab arm were DLT evaluable, defined as the participants who completed the DLT observation period and those participants who discontinued early due to the development of a DLT. The participants were analyzed as treated.

Groups in this outcome

Part 1: Cemiplimab + Chemotherapy

Participants received cemiplimab plus platinum-based doublet chemotherapy

Part 1: Cemiplimab+AbbrevChemo+Ipilimumab

Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab

Part 1: Chemotherapy

Participants received platinum-based doublet chemotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 1: Cemiplimab + Chemotherapy0
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab10
Part 1: Chemotherapy0

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG001
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      10
    3. group Id
      OG002
      value
      0
    units
    Participants
description
Part 1 only
groups
  1. description
    Participants received cemiplimab plus platinum-based doublet chemotherapy
    id
    OG000
    title
    Part 1: Cemiplimab + Chemotherapy
  2. description
    Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab
    id
    OG001
    title
    Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
  3. description
    Participants received platinum-based doublet chemotherapy
    id
    OG002
    title
    Part 1: Chemotherapy
param Type
COUNT_OF_PARTICIPANTS
population Description
Only the first 10 participants enrolled in the Cemiplimab+AbbrevChemo+ipilimumab arm were DLT evaluable, defined as the participants who completed the DLT observation period and those participants who discontinued early due to the development of a DLT. The participants were analyzed as treated.
reporting Status
POSTED
time Frame
28 days
title
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice